Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

About this Study

Crohn's disease (CD) is a relapsing and remitting form of inflammatory bowel disease (IBD) that causes gastrointestinal signs and symptoms of diarrhea, abdominal pain, weight loss, and the passage of blood or mucous per rectum. The inflammation of CD can involve the mucosal surface of the gastrointestinal tract and penetrate through the full thickness of the gastrointestinal

Sponsor Protocol ID:GS-US-419-3895
IRB Number:2019-0308
Actively Enrolling
Interventional
Phase 3
January 08, 2020
Eligibility Criteria
18 years old
75 years old
Both Male and Female
No
No
No

Inclusion Criteria Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of the screening visit


Categories Click category to view its trials.
Digestive Conditions
Participating Locations
Belhaven - University Physicians
University Hospital
Contact Information
Contact Name: Olivia Henry
Phone Number: 601-984-4540
Email: ohenry@umc.edu
Principal Investigator:Glover, Sarah C, D.O.
How to participate in our Clinical Trials